Loading...
XNASMDXH
Market cap55mUSD
Dec 23, Last price  
2.17USD
1D
-3.98%
1Q
-13.89%
IPO
-81.92%
Name

MDxHealth SA

Chart & Performance

D1W1MN
XNAS:MDXH chart
P/E
—
P/S
0.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
35.08%
Rev. gr., 5y
19.89%
Revenues
70m
+89.43%
525,9733,649,1333,657,1683,850,5834,209,7053,650,6393,372,7883,482,5994,918,4017,554,00011,479,00017,467,00029,867,00040,508,00028,338,00011,785,00018,372,00022,239,00037,054,00070,193,000
Net income
-43m
L-14.12%
000000000-16,175,000-15,256,000-14,473,000-13,174,000-12,288,000-32,450,000-43,100,000-30,007,000-30,877,000-50,188,000-43,100,000
CFO
-21m
L-36.99%
000000000-14,105,000-18,513,000-14,394,000-16,585,000-10,489,000-28,543,000-22,289,000-20,244,000-22,548,000-34,118,000-21,497,000
Earnings
Mar 01, 2025

Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
URL
https://mdxhealth.com/
IPO date
Jun 26, 2006
Employees
252
Domiciled in
BE
Incorporated in
BE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
70,193
89.43%
37,054
66.62%
22,239
21.05%
Cost of revenue
92,565
75,513
26,154
Unusual Expense (Income)
NOPBT
(22,372)
(38,459)
(3,915)
NOPBT Margin
Operating Taxes
1,000
6,144
1,875
Tax Rate
NOPAT
(22,373)
(44,603)
(5,790)
Net income
(43,100)
-14.12%
(50,188)
62.54%
(30,877)
2.90%
Dividends
Dividend yield
Proceeds from repurchase of equity
39,599
68,566
BB yield
Debt
Debt current
2,123
1,788
5,281
Long-term debt
44,200
42,268
13,739
Deferred revenue
Other long-term liabilities
63,259
53,537
1,466
Net debt
23,180
28,553
(39,478)
Cash flow
Cash from operating activities
(21,497)
(34,118)
(22,548)
CAPEX
(2,747)
(4,163)
(896)
Cash from investing activities
(3,931)
(29,163)
(885)
Cash from financing activities
32,280
20,841
66,498
FCF
(24,424)
(47,479)
(7,101)
Balance
Cash
22,380
15,503
58,498
Long term investments
763
Excess cash
19,633
13,650
57,386
Stockholders' equity
(145,969)
(155,336)
(116,885)
Invested Capital
257,229
257,981
180,806
ROIC
ROCE
EV
Common stock shares outstanding
25,911
15,866
12,194
Price
Market cap
EV
EBITDA
(15,513)
(33,550)
(879)
EV/EBITDA
Interest
5,582
6,144
1,875
Interest/NOPBT